Park Ki Deok, Lee Woo Yong, Lee Jihae, Park Min-Ho, Ahn Jae Ki, Park Yongbum
Department of Rehabilitation Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Republic of Korea.
Pain Physician. 2016 May;19(4):E547-57.
Trochanteric bursa injections of corticosteroids and local anesthetics have been shown to provide pain relief for the treatment of greater trochanteric pain syndrome (GTPS). However, symptom recurrence and incomplete symptom relief are common. The reason for the variation in response is unclear but may be related to disease-, treatment-, or patient-related factors.
To determine whether there are factors related to patient, treatment, or disease that can predict either the magnitude or duration of response to ultrasound-guided trochanteric bursa injections for GTPS.
Retrospective evaluation.
A university hospital outpatient center.
Potential study participants were patients who underwent ultrasound-guided trochanteric bursa injection at an outpatient rehabilitation department. Follow-up interviews were performed in a hospital visit at 1, 3, and 6 months after injection. The Harris Hip Score and the Verbal Numeric Pain Scale were used to evaluate clinical effectiveness of pain reduction and functional improvement at baseline, 1, 3, and 6 months after treatment. Clinical data and ultrasound findings were obtained to assess the possible predictive factors for a good and durable response to ultrasound-guided trochanteric bursa injection.
Patients receiving ultrasound-guided trochanteric bursa injections had a statistically significant improvement in pain and hip function at 1, 3, and 6 months after the last injections. Of the 137 patients, 110 (80.3%), 95 (64.9%), and 77 (56.2%) patients achieved successful outcomes according to their 1, 3, and 6-month follow-up evaluations, respectively. Univariate analysis showed that patients with knee osteoarthritis and lumbar facet joint or sacroiliac joint pain experienced less therapeutic effect than those without the conditions at 6 months post-injection. Logistic regression analysis showed that the significant outcome predictors at the 6-month follow-up were facet joint or S-I joint pain (odds ratio = 0.304, P = .014) and knee osteoarthritis (odds ratio = 0.329, P = .021). Age, gender, body mass index, and pain duration were not independent predictors of a clinically successful outcome. There was no statistically significant association between effective treatment and the ultrasound findings of tendinosis, bursitis, partial or full-thickness tear, and enthesopathic changes.
Retrospective chart review without a control group.
This study suggests that knee osteoarthritis and lower back pain might be associated with a poor outcome of ultrasound-guided trochanteric bursa injection for GTPS. Assessment of these clinical factors should be incorporated into the evaluation and counseling of patients with GTPS who are candidates for ultrasound-guided trochanteric bursa injection.
Bursa injection, corticosteroid, greater trochanteric pain syndrome, knee osteoarthritis, lower back pain, lumbar facet joint, ultrasonography, S-I joint pain.
已证实向转子囊注射皮质类固醇和局部麻醉剂可缓解大转子疼痛综合征(GTPS)的疼痛。然而,症状复发和症状缓解不完全的情况很常见。反应差异的原因尚不清楚,但可能与疾病、治疗或患者相关因素有关。
确定是否存在与患者、治疗或疾病相关的因素,可预测超声引导下转子囊注射治疗GTPS的反应程度或持续时间。
回顾性评估。
大学医院门诊中心。
潜在研究参与者为在门诊康复科接受超声引导下转子囊注射的患者。在注射后1、3和6个月的医院随访中进行随访访谈。使用Harris髋关节评分和数字疼痛量表评估治疗前、治疗后1、3和6个月疼痛减轻和功能改善的临床效果。获取临床数据和超声检查结果,以评估超声引导下转子囊注射获得良好持久反应的可能预测因素。
接受超声引导下转子囊注射的患者在最后一次注射后1、3和6个月时,疼痛和髋关节功能有统计学意义的改善。在137例患者中,根据1、3和6个月的随访评估,分别有110例(80.3%)、95例(64.9%)和77例(56.2%)患者取得了成功的治疗效果。单因素分析显示,患有膝关节骨关节炎以及腰椎小关节或骶髂关节疼痛的患者在注射后6个月时的治疗效果不如无这些情况的患者。Logistic回归分析显示,6个月随访时的显著结果预测因素为小关节或骶髂关节疼痛(比值比=0.304,P=0.014)和膝关节骨关节炎(比值比=0.329,P=0.021)。年龄、性别、体重指数和疼痛持续时间不是临床治疗成功的独立预测因素。有效治疗与肌腱病、滑囊炎、部分或全层撕裂以及附着点病改变的超声检查结果之间无统计学意义的关联。
无对照组的回顾性病历审查。
本研究表明,膝关节骨关节炎和下背部疼痛可能与超声引导下转子囊注射治疗GTPS的不良结果相关。在对拟接受超声引导下转子囊注射的GTPS患者进行评估和咨询时,应纳入对这些临床因素的评估。
囊内注射;皮质类固醇;大转子疼痛综合征;膝关节骨关节炎;下背部疼痛;腰椎小关节;超声检查;骶髂关节疼痛